141 related articles for article (PubMed ID: 23052641)
1. Plasma factor Xa inhibition can predict antithrombotic effects of oral direct factor Xa inhibitors in rabbit atherothrombosis models.
Funatsu T; Yamashita A; Kaku S; Iwatsuki Y; Asada Y
Thromb Haemost; 2012 Nov; 108(5):896-902. PubMed ID: 23052641
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Iwatsuki Y; Sato T; Moritani Y; Shigenaga T; Suzuki M; Kawasaki T; Funatsu T; Kaku S
Eur J Pharmacol; 2011 Dec; 673(1-3):49-55. PubMed ID: 22040919
[TBL] [Abstract][Full Text] [Related]
3. Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Biemond BJ; Perzborn E; Friederich PW; Levi M; Buetehorn U; Büller HR
Thromb Haemost; 2007 Mar; 97(3):471-7. PubMed ID: 17334516
[TBL] [Abstract][Full Text] [Related]
4. Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis.
Parry TJ; Huang Z; Chen C; Connelly MA; Perzborn E; Andrade-Gordon P; Damiano BP
Blood Coagul Fibrinolysis; 2011 Dec; 22(8):720-6. PubMed ID: 21986468
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic and anticoagulant effects of direct factor Xa inhibitor darexaban in rat and rabbit models of venous thrombosis.
Kaku S; Uemura T; Saitoh M; Suzuki K; Iwatsuki Y; Funatsu T; Kawasaki T
Eur J Pharmacol; 2013 Jan; 699(1-3):40-7. PubMed ID: 23200896
[TBL] [Abstract][Full Text] [Related]
6. Antithrombotic and anticoagulant profiles of TAK-442, a novel factor Xa inhibitor, in a rabbit model of venous thrombosis.
Kawamura M; Konishi N; Hiroe K; Shofuda K; Imaeda Y; Fujimoto T; Kubo K
J Cardiovasc Pharmacol; 2010 Aug; 56(2):156-61. PubMed ID: 20410831
[TBL] [Abstract][Full Text] [Related]
7. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
[TBL] [Abstract][Full Text] [Related]
8. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
9. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
Samama MM; Martinoli JL; LeFlem L; Guinet C; Plu-Bureau G; Depasse F; Perzborn E
Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
[TBL] [Abstract][Full Text] [Related]
10. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor.
Laux V; Perzborn E; Kubitza D; Misselwitz F
Semin Thromb Hemost; 2007 Jul; 33(5):515-23. PubMed ID: 17629849
[TBL] [Abstract][Full Text] [Related]
11. Effect of the factor Xa inhibitor rivaroxaban on arterial thrombosis in wild-type and apolipoprotein E-deficient mice.
Wagner NM; Dressel T; Schäfer K; Konstantinides S
Thromb Res; 2012 Nov; 130(5):793-8. PubMed ID: 22281071
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions.
Mani H; Hesse C; Stratmann G; Lindhoff-Last E
Thromb Haemost; 2013 Jan; 109(1):127-36. PubMed ID: 23138190
[TBL] [Abstract][Full Text] [Related]
13. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans.
Hashimoto T; Suzuki K; Kihara Y; Iwatsubo T; Miyashita A; Heeringa M; Onkels H; Groenendaal D; Verheggen F; van Marle S; Usui T
Xenobiotica; 2013 Jun; 43(6):534-47. PubMed ID: 23167531
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban: a new oral factor Xa inhibitor.
Perzborn E; Roehrig S; Straub A; Kubitza D; Mueck W; Laux V
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):376-81. PubMed ID: 20139357
[TBL] [Abstract][Full Text] [Related]
15. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
[TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban.
Apostolakis S; Lip GY
Expert Opin Investig Drugs; 2012 Jul; 21(7):1057-64. PubMed ID: 22616561
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptide factor Xa inhibitors III: effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits.
Wong PC; Crain EJ; Watson CA; Zaspel AM; Wright MR; Lam PY; Pinto DJ; Wexler RR; Knabb RM
J Pharmacol Exp Ther; 2002 Dec; 303(3):993-1000. PubMed ID: 12438519
[TBL] [Abstract][Full Text] [Related]
18. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.
Francart SJ; Hawes EM; Deal AM; Adcock DM; Gosselin R; Jeanneret C; Friedman KD; Moll S
Thromb Haemost; 2014 Jun; 111(6):1133-40. PubMed ID: 24401946
[TBL] [Abstract][Full Text] [Related]
19. Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.
Hirayama F; Koshio H; Ishihara T; Hachiya S; Sugasawa K; Koga Y; Seki N; Shiraki R; Shigenaga T; Iwatsuki Y; Moritani Y; Mori K; Kadokura T; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S
J Med Chem; 2011 Dec; 54(23):8051-65. PubMed ID: 21995444
[TBL] [Abstract][Full Text] [Related]
20. Antithrombotic potential of GW813893: a novel, orally active, active-site directed factor Xa inhibitor.
Abboud MA; Needle SJ; Burns-Kurtis CL; Valocik RE; Koster PF; Amour AJ; Chan C; Brown D; Chaudry L; Zhou P; Patikis A; Patel C; Pateman AJ; Young RJ; Watson NS; Toomey JR
J Cardiovasc Pharmacol; 2008 Jul; 52(1):66-71. PubMed ID: 18645410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
